Chevy Chase Trust Reduces Stake in Regeneron Pharmaceuticals

Institutional investor cuts holdings in biotech firm by 1.7% in Q3 2025

Mar. 15, 2026 at 10:04am

Got story updates? Submit your updates here. ›

Chevy Chase Trust Holdings LLC, a major institutional investor, reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the third quarter of 2025, according to a recent SEC filing. The firm now owns 203,152 shares of the biopharmaceutical company's stock, worth approximately $114.2 million.

Why it matters

Regeneron is a prominent biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Changes in major institutional ownership can signal shifts in investor sentiment and market expectations around the company's future performance.

The details

Chevy Chase Trust Holdings sold 3,576 shares of Regeneron during the third quarter, reducing its total position to 203,152 shares. The firm now owns about 0.19% of Regeneron's outstanding stock. Other major institutional investors in Regeneron include Dodge & Cox, Norges Bank, AQR Capital Management, and Loomis Sayles & Co.

  • Chevy Chase Trust Holdings filed its Q3 2025 13F report on March 15, 2026.

The players

Chevy Chase Trust Holdings LLC

A major institutional investor and asset management firm.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, and commercializing biologic therapies for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the shifting landscape of institutional ownership in the biotech sector, as major investors like Chevy Chase Trust adjust their positions in response to market conditions and their own investment strategies.